The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 201–300 of 813
B-cell lymphomas present immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B. J., Shree, T., Liu, C. L., Zhang, L., Czerwinski, D. K., Davis, M. M., Levy, R., et al. (2018) · Blood · doi:10.1182/blood-2018-06-845156 · Cited by 47
García‐Merino, A. (2021) · Cells · doi:10.3390/cells10102560 · Cited by 47
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Vitale, C., Ahn, I. E., Sivina, M., Ferrajoli, A., Wierda, W. G., Estrov, Z. E., Konoplev, S. N., Jain, N., O'Brien, S. M., Farooqui, M. Z. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.138289 · Cited by 46
Eken, A., Cansever, M., Somekh, I., Mizoguchi, Y., Ziętara, N., Okuş, F. Z., Erdem, Ş., Canatan, H., Akyol, Ş., Özcan, A., et al. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00632-5 · Cited by 46
Oelsner, K. T., Guo, Y. P., To, S. B., Non, A. L., & Barkin, S. L. (2017) · BMC Genomics · doi:10.1186/s12864-016-3473-9 · Cited by 47
Ublituximab for the treatment of CD20 positive B-cell malignancies
Babiker, H. M., Glode, A. E., Cooke, L. S., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1459560 · Cited by 45
Liu, M., Deng, H., Mu, J., Li, Q., Pu, Y., Jiang, Y., Deng, Q., & Qian, Z. (2021) · Cancer Science · doi:10.1111/cas.14915 · Cited by 45
FDA-approved therapies for chronic GVHD
Lee, S. J., & Zeiser, R. (2024) · Blood · doi:10.1182/blood.2024026633 · Cited by 44
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond
Migali, C., Milano, M., Trapani, D., Criscitiello, C., Espósito, A., Locatelli, M., Minchella, I., & Curigliano, G. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016658423 · Cited by 44
Thorp, B. C., & Badoux, X. C. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339874 · Cited by 44
Mishra, P. K., Palma, M., Buechel, B., Moore, J., Davra, V., Chu, N., Millman, A., Hallab, N. J., Kanneganti, T., Birge, R. B., et al. (2019) · Nature Materials · doi:10.1038/s41563-018-0271-6 · Cited by 44
Hanna, B. S., Yazdanparast, H., Demerdash, Y., Roessner, P. M., Schulz, R., Lichter, P., Stilgenbauer, S., & Seiffert, M. (2020) · Haematologica · doi:10.3324/haematol.2019.238154 · Cited by 45
Langerbeins, P., & Eichhorst, B. F. (2021) · Acta Haematologica · doi:10.1159/000514071 · Cited by 45
Vitale, C., Salvetti, C., Griggio, V., Porrazzo, M., Schiattone, L., Zamprogna, G., Visentin, A., Vassallo, F., Cassin, R., Rigolin, G. M., et al. (2021) · Blood · doi:10.1182/blood.2020008201 · Cited by 45
Kim, D. W., Tan, E. S., Zhou, J., Schell, M. J., Martinez, M., Yu, J. B., Carballido, E. M., Mehta, R. J., Strosberg, J., Imanirad, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01368-z · Cited by 44
Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009517 · Cited by 43
Targeting ITK signaling for T cell-mediated diseases
Weeks, S., Harris, R., & Karimi, M. A. (2021) · iScience · doi:10.1016/j.isci.2021.102842 · Cited by 43
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43
Qiu, Q., Li, C., Yan, X., Zhang, H., Luo, X., Gao, X., Liu, X., Song, Y., & Deng, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120652 · Cited by 43
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
Pillinger, G., Abdul-Aziz, A. M., Zaitseva, L., Lawes, M. J., MacEwan, D. J., Bowles, K. M., & Rushworth, S. A. (2015) · Scientific Reports · doi:10.1038/srep12949 · Cited by 43
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
Natarajan, G. K., Terrazas, C. A., Oghumu, S., Varikuti, S., Dubovsky, J. A., Byrd, J. C., & Satoskar, A. R. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1057385 · Cited by 42
Self-citationCurrent Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 43
Patel, V. M., Lamothe, B., Ayres, M., Gay, J. P., Cheung, J. P., Balakrishnan, K., Ivan, C., Morse, J., Nelson, M., Keating, M. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.321 · Cited by 42
Colado, A., Genoula, M., Cougoule, C., Franco, J. L. M., Almejún, M. B., Risnik, D., Kviatcovsky, D., Podaza, E., Elías, E. E., Fuentes, F., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0136-x · Cited by 42
Liu, Y., Wang, X., Deng, L., Ping, L., Shi, Y., Zheng, W., Lin, N., Wang, X., Tu, M., Xie, Y., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0754-9 · Cited by 44
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 42
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, S., Mursal, M., Verma, G., Hasan, S. S., & Khan, M. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176484 · Cited by 41
New roles for B cell receptor associated kinases: when the B cell is not the target
Nguyen, P., Niesen, E., & Hallek, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0366-8 · Cited by 41
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice
Riccio, L. G. C., Jeljeli, M. M., Santulli, P., Chouzenoux, S., Doridot, L., Nicco, C., dos Reis, F. M., Abrão, M. S., Chapron, C., & Batteux, F. (2019) · Human Reproduction · doi:10.1093/humrep/dez071 · Cited by 41
Mechanisms of failure of chimeric antigen receptor T-cell therapy
Li, X., & Chen, W. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000548 · Cited by 41
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Maffei, R., Maccaferri, M., Arletti, L., Fiorcari, S., Benatti, S., Potenza, L., Luppi, M., & Marasca, R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100635 · Cited by 43
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
Wiestner, A. U. (2014) · Hematology · doi:10.1182/asheducation-2014.1.125 · Cited by 41
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Self-citationNadeem, A., Ahmad, S. F., Al-Harbi, N. O., Ibrahim, K. E., Siddiqui, N. M., Al‐Harbi, M. M., Attia, S. M., & Bakheet, S. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104441 · Cited by 40
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
Parry, H., Mirajkar, N., Cutmore, N., Zuo, J., Long, H. M., Kwok, M., Oldrieve, C., Hudson, C. D., Stanković, T., Paneesha, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02832 · Cited by 42
If small molecules immunotherapy comes, can the prime be far behind?
Zhang, J., Zhang, Y., Qu, B., Yang, H., Hu, S., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113356 · Cited by 40
Current and emerging therapies for primary central nervous system lymphoma
Yuan, Y., Ding, T., Wang, S., Chen, H., Mao, Y. Q., & Chen, T. (2021) · Biomarker Research · doi:10.1186/s40364-021-00282-z · Cited by 42
Fabbro, S. K., Smith, S. M., Dubovsky, J. A., Gru, A. A., & Jones, J. A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0457 · Cited by 40
Self-citationRegulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj, K. K., Uriepero, A., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943354 · Cited by 41
Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
Fares, A. A., Uribe, C. R. C., Martinez, D., Rehman, T. U., Rondon, C. S., & Sandoval-Sus, J. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042208 · Cited by 39
Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
Devata, S., & Wilcox, R. A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0177-5 · Cited by 40
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
Vitale, C., Montalbano, M. C., Salvetti, C., Boccellato, E., Griggio, V., Boccadoro, M., & Coscia, M. (2020) · Cancers · doi:10.3390/cancers12020282 · Cited by 41
A profile of research on the parasitic trypanosomatids and the diseases they cause
Horn, D. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010040 · Cited by 39
Brown, J. R., Hallek, M. J., & Pagel, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159018 · Cited by 38
Lenalidomide in the treatment of chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313230 · Cited by 40
Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response
Andreotti, A. H., Joseph, R. E., Conley, J. M., Iwasa, J., & Berg, L. J. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053344 · Cited by 38
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
Manna, A., Aulakh, S., Jani, P., Ahmed, S., Akhtar, S., Coignet, M. V., Heckman, M. G., Meghji, Z., Bhatia, K., Sharma, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3412 · Cited by 38
Best, S., Lam, V., Liu, T., Bruss, N., Kittai, A. S., Danilova, O. V., Murray, S., Berger, A., Pennock, N. D., Lind, E. F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0794-0 · Cited by 38
Self-citationTun, A. M., & Ansell, S. M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102042 · Cited by 38
Moreno, C., Muñoz, C., Terol, M. J., Hernández‐Rivas, J., & Villanueva, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02115-1 · Cited by 39
CAR-T cell combination therapies in hematologic malignancies
Zhou, D., Zhu, X., & Xiao, Y. Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00536-0 · Cited by 39
Greil, R., Hutterer, E., Hartmann, T. N., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0155-9 · Cited by 37
Podhorecka, M., Gorący, A., Szymczyk, A., Kowal, M., Ibanez, B., Jankowska‐Łęcka, O., Macheta, A., Nowaczyńska, A., Drab-Urbanek, E., Chocholska, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16148 · Cited by 37
Barrientos, J. C., O'Brien, S. M., Brown, J. R., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., Devereux, S., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.007 · Cited by 37
Self-citationMamand, S., Allchin, R. L., Ahearne, M. J., & Wagner, S. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-32634-5 · Cited by 37
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 39
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future
Spaargaren, M., de Rooij, M. F. M., Kater, A. P., & Eldering, E. (2014) · Oncogene · doi:10.1038/onc.2014.181 · Cited by 37
Patten, P., Ferrer, G., Chen, S., Simone, R., Marsilio, S., Yan, X., Gitto, Z., Yuan, C., Kolitz, J. E., Barrientos, J. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86288 · Cited by 36
Charalambous, A., Schwarzbich, M., & Witzens‐Harig, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_7 · Cited by 36
Ibrutinib in Refractory Classic Hodgkin's Lymphoma
Hamadani, M., Balasubramanian, S., & Hari, P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505857 · Cited by 35
Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases
Dichiara, M., Marrazzo, A., Prezzavento, O., Collina, S., Rescifina, A., & Amata, E. (2017) · ChemMedChem · doi:10.1002/cmdc.201700259 · Cited by 36
Eades, C. P., & Armstrong-James, D. P. H. (2018) · Medical Mycology · doi:10.1093/mmy/myy136 · Cited by 35
Hampel, P. J., Call, T. G., Rabe, K. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0388 · Cited by 35
A new molecular paradigm in mycosis fungoides and Sézary syndrome
Elenitoba‐Johnson, K. S. J., & Wilcox, R. A. (2016) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.11.002 · Cited by 35
Ibrutinib in B lymphoid malignancies
Smith, M. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067302 · Cited by 34
Niemann, C. U., Mora-Jensen, H. I., Dadashian, E. L., Krantz, F., Covey, T. M., Chen, S., Chiorazzi, N., Izumi, R. E., Ulrich, R. G., Lannutti, B. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0650 · Cited by 34
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Christensen, B. W., Zaha, V. G., & Awan, F. T. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2067526 · Cited by 35
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy
McGee, M. C., August, A., & Huang, W. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5covr0620-306r · Cited by 33
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
Randall, M. P., & Spinner, M. A. (2023) · Cancers · doi:10.3390/cancers15184509 · Cited by 34
Aue, G., Sun, C., Liu, D., Park, J.-H., Pittaluga, S., Tian, X., Lee, E., Soto, S., Valdez, J., Marić, I., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800570 · Cited by 33
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
Puzzolo, M. C., Giudice, I. D., Peragine, N., Mariglia, P., Propris, M. S. D., Cappelli, L. V., Trentin, L., Reda, G., Cuneo, A., Molica, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637186 · Cited by 33
Muchtar, E., Koehler, A. B., Johnson, M. J., Rabe, K. G., Ding, W., Call, T. G., Leis, J. F., Kenderian, S. S., Hayman, S. R., Wang, Y., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26388 · Cited by 33
Carpenter, P. A., Kang, H. J., Yoo, K. H., Zecca, M., Cho, B., Lucchini, G., Nemecek, E. R., Schultz, K. R., Stepensky, P., Chaudhury, S., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.021 · Cited by 33
Tavakoli, G. M., Yazdanpanah, N., & Rezaei, N. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00401-y · Cited by 33
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Pleyer, C., Wiestner, A. U., & Sun, C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457147 · Cited by 32
Varikuti, S., Volpedo, G., Saljoughian, N., Hamza, O., Halsey, G., Ryan, N. M., Sedmak, B. E., Seidler, G. R., Papenfuss, T. L., Oghumu, S., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy552 · Cited by 32
Self-citationNoninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation
Fraebel, J., Engelhardt, B. G., & Kim, T. K. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.012 · Cited by 32
Giridhar, K. V., Shanafelt, T. D., Tosh, P. K., Parikh, S. A., & Call, T. G. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1267352 · Cited by 32
Novel and emerging targeted-based cancer therapy agents and methods
Hojjat‐Farsangi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3184-x · Cited by 31
Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., Gentles, A. J., Martinez, E., Zhu, D., Chapman, J. R., et al. (2016) · Blood · doi:10.1182/blood-2016-02-696856 · Cited by 31
Rood, J. J. M., Dormans, P. J. A., van Haren, M. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.05.011 · Cited by 31
Immune Modulation in Hematologic Malignancies
Dhodapkar, M. V., & Dhodapkar, K. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.009 · Cited by 32
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
Stephens, D. M., & Spurgeon, S. E. F. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715592569 · Cited by 32
Lin, C.-H., Elkholy, K. H., Wani, N. A., Ding, L., Hu, P., Barajas, J. M., Yu, L., Zhang, X., Jacob, S. T., Khan, W. N., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0135 · Cited by 31
Luo, W., Li, C., Wu, J., Tang, L., Wang, X., Zhang, Y., Wu, Z., Huang, Z., Xu, J., Kang, Y. J., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.005 · Cited by 31
Host-Directed Therapies for Parasitic Diseases
Singh, B., Varikuti, S., Halsey, G., Volpedo, G., Hamza, O., & Satoskar, A. R. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0439 · Cited by 32
Self-citationCurrent Perspectives on Therapy for Chronic Lymphocytic Leukemia
Awan, F. T., Al‐Sawaf, O., Fischer, K., & Woyach, J. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279099 · Cited by 30
Self-citationMhibik, M., Gaglione, E. M., Eik, D., Kendall, E. K., Blackburn, A., Keyvanfar, K., Baptista, M. J., Ahn, I. E., Sun, C., Qi, J., et al. (2021) · Blood · doi:10.1182/blood.2020009686 · Cited by 30
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Xu, M. M., Pu, Y., Zhang, Y., & Fu, Y. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.007 · Cited by 31
Secondary autoimmune cytopenias in chronic lymphocytic leukemia
Rogers, K. A., & Woyach, J. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.011 · Cited by 31
Self-citationPembrolizumab in classical Hodgkin's lymphoma
Maly, J. J., & Alinari, L. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12770 · Cited by 30
Sterner, R. M., & Kenderian, S. S. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000559 · Cited by 29
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
Burchett, J. R., Dailey, J. M., Kee, S. A., Pryor, D. T., Kotha, A., Kankaria, R. A., Straus, D. B., & Ryan, J. J. (2022) · Cells · doi:10.3390/cells11193031 · Cited by 34
Targeting Interleukin-2 Inducible T-Cell Kinase (ITK) in T-Cell Related Diseases
Zhong, Y., Johnson, A. J., Byrd, J. C., & Dubovsky, J. A. (2014) · Postdoc Journal · doi:10.14304/surya.jpr.v2n6.1 · Cited by 29
Self-citationNyhoff, L. E., Barron, B. L., Johnson, E., Bonami, R. H., Maseda, D., Fensterheim, B. A., Han, W., Blackwell, T. S., Crofford, L. J., & Kendall, P. L. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39657 · Cited by 29
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Davis, J. E., Sharpe, C., Mason, K. D., Tam, C. S. L., Koldej, R. M., & Ritchie, D. S. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03136-2 · Cited by 28
Pleyer, C., Sun, C., Desai, S. H., Ahn, I. E., Tian, X., Nierman, P., Soto, S., Superata, J., Valdez, J., Lotter, J., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1772477 · Cited by 29
Link, C. S., Teipel, R., Heidenreich, F., Rücker‐Braun, E., Schmiedgen, M., Reinhardt, J., Oelschlägel, U., Bonin, M. V., Middeke, J. M., Mütherig, A., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.339 · Cited by 27
Purroy, N., Carabia, J., Abrisqueta, P., Egia‐Mendikute, L., Aguiló, M., Carpio, C. D. C., Palacio, C., Crespo, M., & Bosch, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13557 · Cited by 27
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
Liu, M., Wang, X., Li, Z., Zhang, R., Mu, J., Jiang, Y., Deng, Q., & Sun, L. (2020) · Cancer Science · doi:10.1111/cas.14638 · Cited by 27
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
